PMID: 15232335Jul 3, 2004Paper

A comparison of risperidone-induced weight gain across the age span

Journal of Clinical Psychopharmacology
Daniel J Safer

Abstract

A systematic and comprehensive literature search was performed to determine the extent of weight gain induced by risperidone (RIS) treatment across the age span. The review and pooled data analyses were based on double-blind, open trial, and case series studies containing findings on drug dose, age of subjects, weight gain, duration of treatment, and if available, baseline body weight, body mass index, and the percent of subjects experiencing a prominent RIS-induced weight gain. Drug-induced weight gain per month for youths was defined as recorded weight gain minus the age-expected weight gain. The major findings from pooled data were (1) preadolescent youths received a smaller average daily dose and lower mg/kg/d dose of RIS than adolescents, and adolescents in turn had lower mg/kg/d doses than middle-aged adults; (2) RIS-induced weight gain as a percentage of baseline body weight was most pronounced in the preadolescent years and decreased with advancing age; (3) adults over age 65 experienced little to no RIS-induced weight gain; and (4) RIS treatment led to consistently greater body mass index percentage increases for youths than for adults. Available data thus suggest that across the age span, youths are the most sensitive...Continue Reading

Associated Clinical Trials

References

Sep 1, 1995·Journal of the American Academy of Child and Adolescent Psychiatry·P J LombrosoJ F Leckman
May 1, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·C J McDougleD J Cohen
May 1, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·J L ArmenterosJ Gorman
Jun 1, 1997·Journal of Autism and Developmental Disorders·J P Horrigan, L J Barnhill
Jan 1, 1997·Journal of Child and Adolescent Psychopharmacology·R PerryR R Silva
Apr 29, 1998·Journal of the American Academy of Child and Adolescent Psychiatry·R NicolsonL Sloman
Dec 16, 1998·Journal of Child and Adolescent Psychopharmacology·D L KellyC M Ushchak
Aug 10, 1999·Journal of Clinical Psychopharmacology·T Wetterling, H E Müssigbrodt
Aug 26, 1999·Journal of Child and Adolescent Psychopharmacology·E SzigethyR L Findling
Apr 13, 2000·Journal of the American Academy of Child and Adolescent Psychiatry·R L FindlingJ L Blumer
May 16, 2000·The Journal of Clinical Psychiatry·G L Blackburn
Jul 26, 2000·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·E Weber Reynolds CF3rd
Aug 10, 2000·Journal of Child and Adolescent Psychopharmacology·A ZuddasC Cianchetti
Feb 24, 2001·Journal of Child and Adolescent Psychopharmacology·A MartinJ F Leckman
Mar 10, 2001·The Journal of Clinical Psychiatry·R BruggemanJ A Temlett
Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·J J ReillyB E Gibson
Aug 31, 2001·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·A LabelleF Dunbar
Oct 9, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·G MasiP Brovedani
Oct 20, 2001·Journal of Child and Adolescent Psychopharmacology·J A HellingsS R Schroeder
Oct 30, 2001·The Journal of Clinical Psychiatry·M M SimpsonB T Walsh
Dec 19, 2001·International Journal of Geriatric Psychiatry·J S KennedyA Breier
Jan 5, 2002·The Journal of Clinical Psychiatry·M K RainerM Haushofer
Jan 5, 2002·The New England Journal of Medicine·John G CsernanskyUNKNOWN Risperidone-USA-79 Study Group
Feb 12, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Richard P MaloneMary Anne Delaney
Mar 1, 2002·Nordic Journal of Psychiatry·Anne Mari Sund, Pål Zeiner
Mar 5, 2002·The Journal of Clinical Psychiatry·Yoram Barak
Mar 12, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Gary R GaffneySamuel Kuperman
Mar 12, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Gidi RatzoniRonit Weizman
Apr 2, 2002·The American Journal of Psychiatry·Michael J SernyakRobert Rosenheck
May 15, 2002·Journal of Clinical Psychopharmacology·Pál CzoborJeffrey A Lieberman
Aug 2, 2002·The New England Journal of Medicine·James T McCrackenUNKNOWN Research Units on Pediatric Psychopharmacology Autism Network
Aug 3, 2002·The American Journal of Psychiatry·Michael G AmanUNKNOWN Risperidone Disruptive Behavior Study Group

❮ Previous
Next ❯

Citations

Oct 29, 2009·JAMA : the Journal of the American Medical Association·Christoph U CorrellAnil K Malhotra
Mar 19, 2013·European Child & Adolescent Psychiatry·José María Martínez-OrtegaManuel Gurpegui
Jul 17, 2007·Journal of Child and Adolescent Psychopharmacology·Nick C PatelMelissa P DelBello
Nov 6, 2007·Journal of Child and Adolescent Psychopharmacology·Christoph U Correll, John M Kane
Mar 24, 2006·Journal of Child and Adolescent Psychopharmacology·Daniel J Safer, Julie Magno Zito
May 11, 2007·Journal of Child and Adolescent Psychopharmacology·Julie M ZitoDonald R Mattison
Dec 29, 2010·Journal of Child and Adolescent Psychopharmacology·Geneviève RoyLeila Ben Amor
Aug 20, 2011·Journal of Child and Adolescent Psychopharmacology·Daniel J Safer
Apr 27, 2010·Journal of Child and Adolescent Psychopharmacology·Laurel A WeaverBarbara J Coffey
Dec 15, 2011·Journal of Child and Adolescent Psychopharmacology·Lawrence Maayan, Christoph U Correll
Oct 8, 2009·International Clinical Psychopharmacology·Harith S SwadiCandace M Bobier
Jan 1, 2011·BMJ Case Reports·Hira Ahmed, Hala Ali
Sep 17, 2008·Child and Adolescent Psychiatry and Mental Health·Julie M ZitoLaurence L Greenhill
Mar 12, 2010·Child and Adolescent Psychiatry and Mental Health·Erik Parens, Josephine Johnston
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel M GreenLeslie L Robison
Jun 22, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·David M GardnerPaul Waraich
Dec 3, 2011·CNS Drugs·James L RoerigJames E Mitchell
Apr 3, 2014·Journal of Child and Adolescent Psychopharmacology·Mehmet BurcuDaniel J Safer
Aug 26, 2014·Journal of the American Academy of Child and Adolescent Psychiatry·Amanda R KreiderDavid M Rubin
Sep 27, 2007·International Review of Psychiatry·Anil K MalhotraJohn M Kane
Jul 1, 2010·Expert Review of Neurotherapeutics·Lawrence Maayan, Christoph U Correll
Nov 18, 2014·Expert Opinion on Drug Safety·Richard MusilMichael Hamerle
Jul 14, 2010·L'Encéphale·J-L GoebR Jardri
Jan 5, 2008·Journal of the American Academy of Child and Adolescent Psychiatry·Christoph U Correll
Dec 27, 2008·Journal of Psychiatric Research·Stefan GebhardtFrank M Theisen
Feb 9, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ayten ErdoganIbrahim Balcioglu
Dec 3, 2005·Child and Adolescent Psychiatric Clinics of North America·Christoph U CorrellAnil K Malhotra
Nov 8, 2008·Annals of the New York Academy of Sciences·Donald L Gilbert
Mar 15, 2006·Ambulatory Pediatrics : the Official Journal of the Ambulatory Pediatric Association·William O CooperWayne A Ray
Jul 13, 2006·Journal of the American Academy of Child and Adolescent Psychiatry·Christoph U Correll, Harold E Carlson
Aug 30, 2016·Current Addiction Reports·Robert Miranda, Hayley Treloar
Jun 25, 2015·Pharmacogenomics·Angela M Devlin, Constadina Panagiotopoulos
Apr 29, 2015·Journal of Child and Adolescent Psychopharmacology·Angie Mae RoddayLaurel K Leslie
Jan 21, 2015·American Journal of Public Health·Lauren D GarfieldRamesh Raghavan
May 13, 2014·Journal of Child and Adolescent Psychopharmacology·Tanya EbertAnca Ram
May 23, 2016·European Child & Adolescent Psychiatry·Inmaculada BaezaJosefina Castro-Fornieles
Jul 9, 2008·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Garry WalterJoseph Rey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Related Papers

Journal of the American Academy of Child and Adolescent Psychiatry
Gidi RatzoniRonit Weizman
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Linmarie SikichJeffrey A Lieberman
Journal of the American Academy of Child and Adolescent Psychiatry
Scott W WoodsThomas H McGlashan
Journal of the American Academy of Child and Adolescent Psychiatry
Christoph U Correll, Harold E Carlson
© 2022 Meta ULC. All rights reserved